Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
Amyloid-beta peptide (Aβ)-directed active and passive immunization therapeutic strategies reduce brain levels of Aβ, decrease the severity of beta-amyloid plaque pathology and reverse cognitive deficits in mouse models of Alzheimer's disease (AD). As an alternative approach to passive immunizat...
Main Authors: | Susann Cattepoel, Michael Hanenberg, Luka Kulic, Roger M Nitsch |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3071717?pdf=render |
Similar Items
-
Construction and characterization of the HPr-specific Jel42 scFv antibody fragment
by: Smallshaw, Joan Elizabeth
Published: (1997) -
Production of scFv-conjugated affinity silk powder by transgenic silkworm technology.
by: Mitsuru Sato, et al.
Published: (2012-01-01) -
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
by: Chung Hyo Kang, et al.
Published: (2020-12-01) -
scFv Antibody: Principles and Clinical Application
by: Zuhaida Asra Ahmad, et al.
Published: (2012-01-01) -
Purificaiton and characterization of scFv against warfarin
by: 張嘉豪
Published: (2005)